VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q1 2026
Holdings as of Mar 31, 2026, filed May 15, 2026. Long positions only; changes compare share counts with Q4 2025.
- Positions
- 33
- +6 vs. Q4 2025
- Portfolio value
- $2.68B
- +$654.6M (+32.3%) vs. Q4 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| XFORX4 Pharmaceuticals, Inc | COM NEW | 330,525 | $1.37M | 0.1% | +330,525 | New | History |
| ARTVArtiva Biotherapeutics, Inc. | COM | 1,609,569 | $10.4M | 0.4% | 00.0% | Unchanged | History |
| ANROAlto Neuroscience, Inc. | COM SHS | 500,000 | $11.2M | 0.4% | +500,000 | New | History |
| KRROKorro Bio, Inc. | COM | 1,009,500 | $11.4M | 0.4% | +1,009,500 | New | History |
| SEPNSepterna, Inc. | COM | 506,056 | $12.2M | 0.5% | −104,752−17.1% | Reduced | History |
| SRZNSurrozen, Inc. | COM NEW | 632,931 | $18.4M | 0.7% | 00.0% | Unchanged | History |
| HELPHelus Pharma Inc. | COM NEW | 3,851,654 | $18.5M | 0.7% | +11,404+0.3% | Added | History |
| CGEMCullinan Therapeutics, Inc. | COM | 1,379,965 | $19.6M | 0.7% | 00.0% | Unchanged | History |
| IPSCCentury Therapeutics, Inc. | COM | 8,695,652 | $19.7M | 0.7% | +8,695,652 | New | History |
| ANLAdlai Nortye Group Ltd. | ADS | 3,212,731 | $22.2M | 0.8% | +3,212,731 | New | History |
| TENXTenax Therapeutics, Inc. | COM NEW | 1,675,262 | $26.8M | 1.0% | +1,675,262 | New | History |
| ENGNenGene Therapeutics Inc. | COM | 4,771,414 | $32.5M | 1.2% | 00.0% | Unchanged | History |
| RLMDRelmada Therapeutics, Inc. | COM | 4,843,380 | $33.7M | 1.3% | +4,843,380 | New | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 6,434,990 | $38.3M | 1.4% | +1,089,875+20.4% | Added | History |
| CBIOCrescent Biopharma, Inc. | COM | 2,133,576 | $39.2M | 1.5% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 2,173,913 | $39.4M | 1.5% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM NEW | 3,220,364 | $45.2M | 1.7% | 00.0% | Unchanged | History |
| CTMXCytomX Therapeutics, Inc. | COM | 9,982,124 | $46.9M | 1.8% | −5,579,376−35.9% | Reduced | History |
| MAZEMaze Therapeutics, Inc. | COM | 1,602,034 | $47.8M | 1.8% | +53,465+3.5% | Added | History |
| VORVor Biopharma Inc. | COM NEW | 3,041,719 | $54.3M | 2.0% | +1,097,953+56.5% | Added | History |
| ORICOric Pharmaceuticals, Inc. | COM | 4,319,765 | $54.7M | 2.0% | −1,356,465−23.9% | Reduced | History |
| ELVNEnliven Therapeutics, Inc. | COM | 1,726,331 | $67.7M | 2.5% | −1,500,000−46.5% | Reduced | History |
| SVRASavara Inc | COM | 13,740,375 | $75.0M | 2.8% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,882,709 | $75.9M | 2.8% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 2,000,000 | $77.0M | 2.9% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 10,346,926 | $87.6M | 3.3% | +3,031,379+41.4% | Added | History |
| DMRADamora Therapeutics, Inc. | COM NEW | 3,603,595 | $93.3M | 3.5% | +3,603,595 | New | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,180,000 | $99.0M | 3.7% | +180,000+18.0% | Added | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 6,474,485 | $130.3M | 4.9% | −254,500−3.8% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 3,685,448 | $185.9M | 6.9% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 4,148,428 | $203.5M | 7.6% | 00.0% | Unchanged | History |
| ERASErasca, Inc. | COM | 16,382,812 | $265.1M | 9.9% | −1,474,271−8.3% | Reduced | History |
| APGEApogee Therapeutics, Inc. | COM | 8,493,321 | $714.9M | 26.7% | 00.0% | Unchanged | History |
Sold out since Q4 2025 (2)
Positions held at the end of Q4 2025 that are gone from this filing.